Comparative Pharmacology
Head-to-head clinical analysis: CAP PROFEN versus PREVACID NAPRAPAC 500 COPACKAGED.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CAP PROFEN versus PREVACID NAPRAPAC 500 COPACKAGED.
CAP-PROFEN vs PREVACID NAPRAPAC 500 (COPACKAGED)
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CAP-PROFEN is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes, reducing prostaglandin synthesis and resulting in anti-inflammatory, analgesic, and antipyretic effects.
Lansoprazole inhibits gastric acid secretion by irreversibly binding to the H+/K+ ATPase (proton pump) in gastric parietal cells. Naproxen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis.
200-400 mg orally every 4-6 hours as needed; maximum 1200 mg/day.
One tablet of naproxen 500 mg and one capsule of lansoprazole 15 mg taken together orally once daily. Naproxen component: 500 mg orally twice daily. Lansoprazole component: 15 mg orally once daily.
None Documented
None Documented
2-4 hours (terminal half-life); prolonged in elderly (up to 6 h) and renal impairment.
Naproxen: 12–17 hours (mean ~14 h), prolonged with renal impairment. Esomeprazole: 1–1.5 hours (increase to 2–3 h with CYP2C19 poor metabolizers or hepatic impairment).
Primarily renal (70-80% as unchanged drug and glucuronide conjugate), with 10-15% biliary/fecal. Less than 5% unchanged in urine.
Naproxen: 95% renal (primarily as unchanged drug and metabolites, including 6-O-desmethyl naproxen), <5% biliary/fecal. Esomeprazole: 80% renal (as metabolites, primarily hydroxyesomeprazole and desmethyl-esomeprazole, with ~1% unchanged), 20% fecal (via bile).
Category C
Category C
Opioid and NSAID Combination
Proton Pump Inhibitor/NSAID Combination